EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 r...
ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase 2 results with camidanlumab tesirine (cami) in relapsed/refractory